The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients

Arthritis Research and Therapy

Volumn 15, Issue 4, 2013, Pages

  Plasencia, Chamaida ^a   Pascual Salcedo, Dora ^a   García Carazo, Sara ^a   Lojo, Leticia ^a   Nuño, Laura ^a   Villalba, Alejandro ^a   Peiteado, Diana ^a   Arribas, Florencia ^a   Díez, Jesus ^a   López Casla, Maria Teresa ^a   Martín Mola, Emilio ^a   Balsa, Alejandro ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ANTIBODY; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGENICITY; MALE; SPONDYLARTHRITIS; ANTAGONISTS AND INHIBITORS; BLOOD; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIBODIES; ANTIRHEUMATIC AGENTS; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; SPONDYLARTHRITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880948914     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4258     Document Type: Article

References (55)

1. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011, 377:2127-2137. 10.1016/S0140-6736(11)60071-8, 21684383.
2. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002, 346:1349-1356. 10.1056/NEJMoa012664, 11986408.
3. Davis JC, van der HD, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003, 48:3230-3236. 10.1002/art.11325, 14613288.
4. Brandt J, Haibel H, Sieper J, Reddig J, Braun J. Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum 2001, 44:2936-2937. 10.1002/1529-0131(200112)44:12<2936::AID-ART483>3.0.CO;2-M, 11762956.
5. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000, 43:1346-1352. 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E, 10857793.
6. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002, 29:118-122.
7. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003, 48:2224-2233. 10.1002/art.11104, 12905476.
8. van den Bosch F, Kruithof E, Baeten D, De KF, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000, 59:428-433. 10.1136/ard.59.6.428, 1753171, 10834859.
9. van den Bosch F, Kruithof E, Baeten D, Herssens A, De KF, Mielants H, Veys EM. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002, 46:755-765. 10.1002/art.511, 11920412.
10. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002, 1:457-462. 10.1038/nrd818, 12119747.
11. Lie E, van der HD, Uhlig T, Mikkelsen K, Rodevand E, Koldingsnes W, Kaufmann C, Kvien TK. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 2011, 70:157-163. 10.1136/ard.2010.131797, 21062852.
12. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005, 44:670-676. 10.1093/rheumatology/keh584, 15757965.
13. de KF, Baeten D, Van den BF, Kruithof E, Mielants H, Veys EM. Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety, and biological immunomodulation. Rheum Dis Clin North Am 2003, 29:463-479. 10.1016/S0889-857X(03)00052-8, 12951862.
14. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Rudwaleit M, Sieper J, Braun J. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004, 31:531-538.
15. Heldmann F, Brandt J, van der Horst-Bruinsma IE, Landewe R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Geusens P, Gaston H, Schewe S, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Listing J, Braun J. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011, 29:672-680.
16. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, Freundlich B. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011, 63:1543-1551.
17. de Vries MK, Wolbink GJ, Stapel SO, de VH, van Denderen JC, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007, 66:1252-1254. 10.1136/ard.2007.072397, 1955152, 17472991.
18. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549. 10.1016/S0140-6736(02)08512-4, 12047962.
19. de Vries MK, Wolbink GJ, Stapel SO, de Groot ER, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis 2007, 66:133-134. 1798422, 17178760.
20. de Vries MK, Brouwer E, van der Horst-Bruinsma IE, Spoorenberg A, van Denderen JC, Jamnitski A, Nurmohamed MT, Dijkmans BA, Aarden LA, Wolbink GJ. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009, 68:1787-1788. 10.1136/ard.2009.109702, 19822712.
21. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010, 69:817-821. 10.1136/ard.2009.112847, 19581278.
22. Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van SD, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011, 70:284-288. 10.1136/ard.2010.135111, 21068090.
23. van der LS, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368. 10.1002/art.1780270401, 6231933.
24. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P, Qureshi AA, Soriano ER, Taylor WJ. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009, 68:1387-1394. 10.1136/ard.2008.094946, 2719080, 18952643.
25. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:18-24.
26. Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D. Ankylosing Spondylitis Disease Activity Score (ASDAS); defining cut-off values for disease activity state and improvement scores. Ann Rheum Dis 2011, 70:47-53. 10.1136/ard.2010.138594, 21068095.
27. Hart MH, de VH, Wouters D, Wolbink GJ, Killestein J, de Groot ER, Aarden LA, Rispens T. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011, 372:196-203. 10.1016/j.jim.2011.07.019, 21824477.
28. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore D, Ruiz Del Agua A, Martínez A, Aarden L, Martín-Mola E, Balsa A. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011, 50:1445-1452. 10.1093/rheumatology/ker124, 21427177.
29. Wolbink GJ, Voskuyl AE, Lems WF, de GE, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:704-707. 10.1136/ard.2004.030452, 1755482, 15485995.
30. Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Griep EN, Limburg PC, Kallenberg CG, Wolbink GJ, Brouwer E. The formation of autoantibodies to TNF-α blocking agents in relation to clinical response in patients with ankilosing spondylitis. Clin Exp Rheumatol 2010, 28:661-668.
31. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA, Wolbink GJ. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:531-535. 10.1136/ard.2008.089979, 18375542.
32. Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken) 2010, 62:1362-1369. 10.1002/acr.20258, 20506310.
33. Stone MA, Payne U, Pacheco-Tena C, Inman RD. Cytokine correlate of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004, 63:84-87. 10.1136/ard.2003.006916, 1754729, 14672897.
34. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004, 63:665-670. 10.1136/ard.2003.016386, 1755042, 15037444.
35. Davis JC, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, Inman RD, de Vries T, Tsuji WH. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005, 32:1751-1754.
36. Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008, 67:1276-1281.
37. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, Carcereri-De-Prati R, Kupper H, Kary S. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009, 36:801-808. 10.3899/jrheum.081048, 19273449.
38. Pavelka K, Forejtova S, Stolfa J, Chroust K, Buresova L, Mann H, Vencovský J. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol 2009, 27:958-963.
39. Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010, 49:563-570. 10.1093/rheumatology/kep422, 2820265, 20032223.
40. Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005, 32:2183-2185.
41. Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADAER. Arthritis Res Ther 2006, 8:R72. 10.1186/ar1941, 1526631, 16620398.
42. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411. 10.1002/art.20217, 15146409.
43. Sidiropoulos PI, Boumpas DT. Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006, 65:701-703. 10.1136/ard.2005.049890, 1798160, 16699049.
44. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006, 33:31-36.
45. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563. 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W, 9751087.
46. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlate with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1739-1745. 10.1136/ard.2008.092833, 19019895.
47. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de GE, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:711-715. 10.1002/art.21671, 16508927.
48. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007, 46:1828-1834. 10.1093/rheumatology/kem261, 18032541.
49. van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, Beckmann C, Unnebrink K, Kupper H. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 2008, 27:1021-1028. 10.1007/s10067-008-0866-4, 2468311, 18350329.
50. van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 2008, 67:1697-1701. 10.1136/ard.2007.083683, 18245109.
51. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006, 54:3782-3789. 10.1002/art.22214, 17133559.
52. Plasencia C, Pascual-Salcedo D, Nuno L, Bonilla G, Villalba A, Peiteado D, Díez J, Nagore D, del Agua AR, Moral R, Martin-Mola E, Balsa A. Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012, 71:1955-1960. 10.1136/annrheumdis-2011-200828, 22563028.
53. Ducourau E, Mulleman D, Paintaud G, Chu Miow LD, Lauferon F, Ternant D, Watier H, Goupillel P. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011, 13:R105. 10.1186/ar3386, 3218920, 21708018.
54. Aybay C, Ozel S, Aybay C. Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol Int 2006, 26:473-480. 10.1007/s00296-005-0085-0, 16341700.
55. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010, 69:2002-2008. 10.1136/ard.2009.124446, 20511613.